| Autor: |
Markova KV; Pediatric Research and Clinical Center for Infectious Diseases of the Federal Medical Biological Agency, St. Petersburg, Russia., Skripchenko EY; Pediatric Research and Clinical Center for Infectious Diseases of the Federal Medical Biological Agency, St. Petersburg, Russia.; Saint-Petersburg State Pediatric Medical University, St. Petersburg, Russia., Skripchenko NV; Pediatric Research and Clinical Center for Infectious Diseases of the Federal Medical Biological Agency, St. Petersburg, Russia.; Saint-Petersburg State Pediatric Medical University, St. Petersburg, Russia., Marchenko NV; Pediatric Research and Clinical Center for Infectious Diseases of the Federal Medical Biological Agency, St. Petersburg, Russia., Shevchenko EY; Pediatric Research and Clinical Center for Infectious Diseases of the Federal Medical Biological Agency, St. Petersburg, Russia., Ivanova GP; Pediatric Research and Clinical Center for Infectious Diseases of the Federal Medical Biological Agency, St. Petersburg, Russia., Vishnevetskaya EM; Pediatric Research and Clinical Center for Infectious Diseases of the Federal Medical Biological Agency, St. Petersburg, Russia. |
| Abstrakt: |
Infections transmitted by ixodic ticks in childhood account for about 20%, and tick-borne encephalitis accounts for up to 25% of cases. A feature of the course of tick-borne encephalitis is unpredictability and the possibility of chronization in 1-3% of cases with late diagnosis and inadequate therapy. The article presents a clinical observation of the disease in a child whose chronically progressive course of amyotrophic form was diagnosed 1 year and 8 months after the onset of the disease. The presence of anamnestic data, features of clinical manifestations in the dynamics and typical neurovirualization picture of the disease, even with negative results of serological and molecular genetic studies of blood and cerebrospinal fluid, allowed to make a diagnosis, prescribe etio-pathogenetic therapy and thereby stabilize the patient's condition. The use of complex drugs in the treatment, such as Cytoflavin, allows to optimize the course of the disease. |
